Li Yang
No. 17, Block 3, Southern Renmin Road
Chengdu, 610041, China
Chengdu, 610041, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Production of SARS-CoV-2 virus-like particles as a vaccine candidate in stable cell lines through inducible E and M protein expression.
Journal: BMC biotechnology
Published: April 07, 2025
A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants.
Journal: Signal transduction and targeted therapy
Published: November 24, 2024
Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages.
Journal: Signal transduction and targeted therapy
Published: November 21, 2024
Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant.
Journal: Nature biomedical engineering
Published: February 11, 2024
Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials.
Journal: Nature communications
Published: September 27, 2023
Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection.
Journal: Signal transduction and targeted therapy
Published: April 03, 2023
Cationic crosslinked carbon dots-adjuvanted intranasal vaccine induces protective immunity against Omicron-included SARS-CoV-2 variants.
Journal: Nature communications
Published: January 03, 2023
Trimeric protein vaccine based on Beta variant elicits robust immune response against BA.4/5-included SARS-CoV-2 Omicron variants.
Journal: Molecular biomedicine
Published: October 08, 2022
A vaccine based on the yeast-expressed receptor-binding domain (RBD) elicits broad immune responses against SARS-CoV-2 variants.
Journal: Frontiers in immunology
Published: August 04, 2022
A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant.
Journal: Nature communications
Published: April 26, 2022
Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants.
Journal: Signal transduction and targeted therapy
Published: February 27, 2022
Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2.
Journal: Signal transduction and targeted therapy
Published: October 13, 2020
Showing 1-12 of 12
Last Updated: 09/26/2026